Filed pursuant to Rule 425

Filed by Thermage, Inc.

Pursuant to Rule 425

Under the Securities Act of 1933 and

Pursuant to Rule 14a-12

Under the Securities Exchange Act of 1934

Subject Company: Thermage, Inc.

Commission File No.: 001-33123


Thermage, Inc.
Thermage, Inc.
(Nasdaq: THRM)
(Nasdaq: THRM)
Stephen Fanning
Stephen Fanning
Chairman and CEO
Chairman and CEO


Additional Information and Where You Can Find It
This
communication
may
be
deemed
to
be
solicitation
material
in
respect
of
the
proposed
transaction
between
Thermage
and
Reliant.
In
connection
with
the
transaction,
Thermage
will
file
a
registration
statement
on
Form
S-4
with
the
SEC
containing
a
proxy
statement/prospectus/information
statement.
The
proxy
statement/prospectus/information
statement
will
be
mailed
to
the
stockholders
of
Thermage
and
Reliant.
Investors
and
security
holders
of
Thermage
and
Reliant
are
urged
to
read
the
proxy
statement/prospectus/information
statement
when
it
becomes
available
because
it
will
contain
important
information
about
Thermage,
Reliant
and
the
proposed
transaction.
The
proxy
statement
/
prospectus/information
statement
(when
it
becomes
available),
and
any
other
documents
filed
by
Thermage
with
the
SEC,
may
be
obtained
free
of
charge
at
the
SEC's
web
site
at
www.sec.gov.
In
addition,
investors
and
security
holders
may
obtain
free
copies
of
the
documents
filed
with
the
SEC
by
Thermage
by
contacting
Thermage
Investor
Relations
by
e-mail
at
IR@thermage.com
or
by
telephone
at
(510)
259-7117.
Investors
and
security
holders
are
urged
to
read
the
proxy
statement/prospectus/information
statement
and
the
other
relevant
materials
when
they
become
available
before
making
any
voting
or
investment
decision
with
respect
to
the
proposed
transaction. 
Thermage
and
its
respective
directors
and
executive
officers
may
be
deemed
to
be
participants
in
the
solicitation
of
proxies
from
its
stockholders
in
favor
of
the
proposed
transaction.
Information
about
the
directors
and
executive
officers
of
Thermage
and
their
respective
interests
in
the
proposed
transaction
will
be
available
in
the
proxy
statement/prospectus/information
statement.
2


Forward Looking Statements
Forward Looking Statements
This presentation contains forward-looking statements within the meaning of
the U.S. Private Securities Litigation Reform Act of 1995, including statements
regarding potential transaction timing, projected financial results, and
anticipated cost savings, synergies and other opportunities. Forward-looking
statements are based on management's current, preliminary expectations and
are subject to risks and uncertainties, which may cause actual results to differ
materially from the statements contained herein, including the risks that the
transaction is delayed or ultimately not consummated, and that the
anticipated financial and operating benefits of the transaction are not realized,
among other risks. Further information on potential risk factors
that could
affect Thermage's business are detailed in the Company's Form 10-Q for the
quarter ended March
31, 2008, and additional risk factors relating to the
proposed transaction discussed in this presentation will be presented in future
public filings. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. Thermage
undertakes no obligation to update publicly any forward-looking statements
to reflect new information, events or circumstances after the date they were
made, or to reflect the occurrence of unanticipated events.
3


Agenda
Agenda
Relay Transaction
Strategic Rationale
Market Opportunity
Combined Company Benefits
Transaction Details Overview
Financial Highlights
Prior to filing the final proxy, communications
regarding the merger are restricted
4


Creating a Global Leader
Creating a Global Leader
Strategic Rationale
Financial Rationale
Combines two of the most differentiated
and valued brands in aesthetic devices
Highly complementary product offering
Targeting the highest growth market
sectors
Strong economies of scale
Significant cross-selling opportunities
Track record of innovation
Creates one of the largest sales forces in
aesthetic devices
Enhanced resources to target international
sales
Unique recurring revenue financial model
Significant cost synergy opportunities
benefiting from proximity of headquarters
Anticipated cash flow generation of over
$15 million in 2009
Expected to be accretive to GAAP EPS in
2009
5


Significant Synergy Opportunity
Significant Synergy Opportunity
EPS Accretive in 2009*
Over $14 million in projected annual costs savings achieved in 12 months
Significant efficiencies created in SG&A and manufacturing
Leverage combined purchasing power
Consolidate administrative activities and close proximity of headquarters
Projected revenue opportunities
Cross-selling
Enhanced consumable opportunities
Potential for product bundling
* As
compared
to
First
Call
2009
consensus
GAAP
EPS
of
$0.26
as
of
July
3,
2008
6


Thermage
Thermage
Leader in skin tightening
Recent introduction of cellulite reduction
Over 500,000 procedures performed since
commercialization in November 2002
Broad Distribution:
Over 80 countries
OUS revenue of almost 50%
Industry’s leading disposables business
model
Unique IP-protected technology
7


Relay
Relay
Leader in skin resurfacing and rejuvenation
Pioneer of fractional resurfacing in 2004
Strong momentum in new product
placements
Broad distribution:
Over 60 countries
OUS revenue of almost 38%
8


Combining Two of the Most Differentiated &
Combining Two of the Most Differentiated &
Valued Brands in Aesthetics
Valued Brands in Aesthetics
Creates one of the largest Aesthetic device
companies in the industry
Strong balance between recurring revenue and new
product placement
Highly differentiated technologies
Large installed base of approximately 4,000 systems
Track record of innovation
9


Aesthetic Market Overview
Aesthetic Market Overview
Key Growth Drivers
Key Growth Drivers
Aging of U.S. Population
Broader Range of Non-invasive Treatments
Changing Practitioner Economics –
managed care and
government reimbursement restrictions
Increased Acceptance of Aesthetic Procedures
Enormous U.S. Aesthetic Market with 11.7 Million Procedures
and $13.5 Billion in Spending in 2007
(1)
(1)  Source: ASAPS Cosmetic Surgery National Data Bank, data derived from core physicians
10


Targeting the Highest Growth Markets
Targeting the Highest Growth Markets
CAGR for U.S. Procedures & Device Sales (2007-2011)
33%
14%
26%
11%
23%
16%
19%
34%
17%
11%
18%
12%
0%
5%
10%
15%
20%
25%
30%
35%
40%
Skin
Tightening
Skin
Rejuvenation
Skin
Resurfacing
Cellulite
Reduction
Hair Removal
Acne
Reduction
No. of Procedures
Device Sales ($MM)
Source: Millennium Research Group 2007 report.
Initial Target Markets
11


Installed Base
Over 1,500
Installed Base
Over 2,500
Cross Selling Opportunities
Cross Selling Opportunities
Cross-Branding
Opportunities
Strong Combination
Therapy
One Stop Shopping
For Physicians
Potential to Bundle
Technology
12


Creating One of the Largest Sales Forces in
Creating One of the Largest Sales Forces in
Aesthetic Devices
Aesthetic Devices
Largest Bifurcated
U.S. Sales Force
Focused on
Disposables
Focused on
Generators
13


Consumable Revenue
Consumable Revenue
2007 Consumable Revenue Per Installed Instrument
Dedicated sales force
focused on consumables
Proven cooperative
marketing campaigns with
physicians
Enhanced resources to
increase visibility with
physicians and patients
$20,300
$13,700
$-
$5,000
$10,000
$15,000
$20,000
$25,000
Thermage
Reliant
14


Creating a Strong Sustainable Business
Creating a Strong Sustainable Business
2007 Revenue Streams
68%
26%
6%
20%
72%
8%
42%
51%
7%
0%
20%
40%
60%
80%
100%
Thermage
Reliant
NewCo
Tips
Systems
Other
15


4/26/06
Eyes by Thermage™
Track Record of Innovation
Track Record of Innovation
10/26/06
2/1/07
ThermaCool®NXT
Tummy by Thermage™
2/2/07
Hands by Thermage™
6/26/07
Lips by Thermage™
8/2/07
ThermaTip™
STC
10/1/07
ThermaTip™
DC and
Body Shape procedure
2/1/08
ThermaTip™
CL (Cellulite)
8/14/06
Fraxel
®
SR1500 Laser
2/2/07
Roller tips
2/2/07
2
Generation
Optical
Tracking™
6/4/07
Fraxel Re:Fine™
Laser System
9/7/07
Fraxel Skin Ecology System
1/31/08
Q1
2007
Q4
Q3
Q4
Q3
Q2
Q1
Q2
Q1
2008
2006
Q1
2007
Q4
Q3
Q4
Q3
Q2
Q1
Q2
Q1
2008
2006
16
nd
Fraxel Re:Pair™
Laser


Transaction Overview
Transaction Overview
Purchase
Consideration
23.6 million shares and $25 million in cash, plus the
assumption of $7.0 million of net debt, for an approximate
total consideration of $95 million, based upon the closing
price of Thermage common stock on July 3, 2008
Pro Forma
Ownership
(treasury stock method)
Thermage:    51.1%
Reliant:         48.9%
Board/Management
Chairman & CEO:   Steve Fanning
CFO:
Jack Glenn
Thermage:
Six Directors
Reliant:
Three Directors
Approvals
Transaction is subject to approval of Thermage stockholders, of
which certain stockholders holding 33%of the shares outstanding
have agreed to vote in favor of the transaction
Reliant stockholders have already approved the transaction by
written consent
Additional customary conditions to closing
Anticipated Timing
To Closing
Fourth Quarter of 2008
17


Combined Financial Strength
Combined Financial Strength
Thermage
2007
Revenue
$63.1
Reliant
2007
Revenue
$70.5
Combined Company
2007
Revenue
$133.6
Shares Outstanding
48 mil.
18


International Sales
International Sales
62%
38%
United States
Rest of World
52%
22%
16%
10%
United States
Asia Pacific
Europe & Middle East
Rest of World
Expansion of international distribution for Reliant products
Greater leverage with distributors
19


$63
$71
$102
$124
$124
$134
$141
$149
$0
$20
$40
$60
$80
$100
$120
$140
$160
THRM
Reliant
CUTR
PMTI
CYNO
NewCo
ELOS
CLZR
Creating Strong Economies of Scale
Creating Strong Economies of Scale
Source: Wall Street Research, and company (Thermage and Reliant)
management.
Strong Economies of Scale
Greater Liquidity
Enhanced Cash Flow
Greater Resources to
Drive R&D
Better Negotiating
Leverage With Suppliers
and Distributors
2007 Revenue
20


Creating a Global Leader
Creating a Global Leader
Strategic Rationale
Financial Rationale
Combines two of the most differentiated
and valued brands in Aesthetics
Highly complementary product offering
Targeting the highest growth market
sectors
Strong economies of scale
Significant cross-selling opportunities
Track record of innovation
Creates one of the largest sales forces in
Aesthetics
Enhanced resources to target international
sales
Unique recurring revenue financial model
Significant cost synergy opportunities
benefiting from proximity of headquarters
Anticipated cash flow generation of over
$15 million in 2009
Expected to be accretive to GAAP EPS in
2009
21